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Data of the patients with systolic heart failure before and after vitamin D
supplementation
Before Vitamin D
Supplementation
After Vitamin D
Supplementation P Value
25-OH vitamin D
level (ng/ml)
11.66  5.12 40.720  14.74 <0.001
6- MWT(m) 461.0  79.97 559.25  71.96 <0.001
LVEF (%) 31.70  3.40 35.50  4.00 <0.001
LVDd (mm) 60.00  9.67 57.95  9.21 <0.001
LVSd (mm) 50.40  6.40 48.10  6.18 <0.001
LA (mm) 42.5  6.50 42.40  6.60 0.818
RA (mm) 38.2  6.06 38.4  6.04 0.729
RV (mm) 37.8  5.81 38.1  5.83 0.670
Calcium (mg/dl) 9.46  0.45 9.64  0.50 0.330
Phosphate (mg/dl) 3.480.97 3.52  0.88 0.681
Sodium (mmol/l) 138.45  3.42 137.75  3.71 0.283
PTH (pg/ml) 62.95  40.40 46.45  32.24 0.120
ALT (U/l) 20.45  9.26 22.15  10.91 0.191
6-MWT indicates 6 minute walk test; LVEF, left ventricle ejection fraction; LVDd, left ventricle
end diastolic diameter; LVSd, left ventricle end systolic diameter; LA, left atrium; RA, right
atrium; RV, right ventricle; PTH, parathyroid hormone; ALT,alanine amotranspherase.
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Effects of Levosimendan and Dobutamine on Systolic Time Intervals in Patients
with Acute Decompensated Heart Failure
Yüksel Çavus¸oglu, Aydın Nadir, Kadir Ugur Mert, Erkan Gencer, Bektas Morrad,
Fezan Mutlu, Taner Ulus
Eskisehir Osmangazi University, Eskisehir
Purpose: Levosimendan has been shown to have a better hemodynamic proﬁle over
dobutamine in increasing cardiac output and reducing pulmonary wedge pressure in
patients with acute decompensated heart failure (HF). Data comparing the effect of
levosimendan with dobutamine on systolic time intervals is lacking. Therefore, the
aim of this study was to evaluate the effects of levosimendan and dobutamine on
systolic time intervals.
Methods: Fifty patients with NYHA class III-IV decompensated HF requiring
inotropic support, LVEF <35% and in sinus rhythm were randomized (in a 1:1
design) to levosimendan (n¼25) or dobutamine (n¼25). Both inotropic agents were
administered as a continuous 24-h infusion (levosimendan at a dose of 0.2 mgr/kg/min
with a preceding bolus dose of 12 mgr/kg and dobutamine at a dose of 10 mgr/kg/min
without a bolus dose). All patients underwent echocardiographic evaluation before
and at the end of inotropic infusion. LVEF, heart rate-corrected electromechanical
systole (QS2i), pre-ejection period (PEP) and left ventricular ejection time (LVET)
were measured.
Results: There was no signiﬁcant difference in baseline clinical characteristics and
laboratory parameters between levosimendan and dobutamine groups. As compared
with their baseline values, LVEF and LVET signiﬁcantly increased at the end of both
levosimendan and dobutamine infusions with a similar extent in both groups (table).
Levosimendan signiﬁcantly shortened QS2i and PEP. Dobutamine shortened PEP, but
showed no effect on QS2i.
Conclusıons: This study suggests that both levosimendan and dobutamine are almost
equally effective in increasing LVET and in shortening PEP. However, levosimendan
appears to have additional advantage over dobutamine in shortening QS2i, indicating
a fairly strong positive inotropic effect.Systolic time intervals during inotropic therapy
Before
Dobutamine
After
Dobutamine p
Before
Levosimendan
After
Levosimendan p
LVEF, % 27.94.6 30.84.7 0.0001 26.05.5 30.65.4 0.0001
QS2i,
ms
54324 53627 0.112 52338 50938 0.003
PEP,
ms
11716 10618 0.0001 12022 10921 0.001
LVET,
ms
24238 25238 0.0001 23028 24025 0.039
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The Better Outcomes Associated with Warfarin use in Patients with Heart
Failure in Either Atrial Fibrillation or Sinus Rhythm
Güliz Kozdag1, Ender Emre1, Gokhan Ertas2, Yasar Akay1, Irem Yilmaz1,
Tayfun Sahin1, Teoman Kilic1, Halil Ekren3, Umut Celikyurt1, Goksel Kahraman1,
Ertan Ural1, Onur Argan1, Dilek Ural1
1Kocaeli University, Faculty of Medicine, Department of Cardiology, Kocaeli,
2Department of Cardiology, _Istanbul Dr. Siyami Ersek Thoracic and Cardiovascular
Surgery, Training and Research Hospital, Istanbul, 3Goverment Hospital, Erzincan
Background: Warfarin use and associated outcomes in patients with chronic heart
failure (HF) have not been well described previously. We hypothesized that warfarin
is associated with lower risks of cardiovascular mortality in patients with sinus
rhythm, atrial ﬁbrillation and pacemaker rhythm.
Methods: We examined the outcomes in patients who were followed –up between
January 2003 and April 2011 in the out-patient clinic due to chronic HF. 671 HF
patients were enrolled into the study group (427 male, 244 female, mean age, 64  13
years; mean ejection fraction, 27  12%, mean NYHA 2.80.5, 62% with coronary
artery disease). 445 patients had sinus rhythm, 165 patients had atrial ﬁbrillation and
61 patients had pacemaker rhythm.
Results: Two hundred -ﬁfty three patients (38%) died due to cardiovascular reasons.
210 (31 %) patients were on warfarin treatment. However 27 patients (63%) who were
not taken warfarin died, 39 patients (%32) who were taken warfarin died in atrial
ﬁbrillation (p<0.001) due to cardiovascular reasons during follow-up. Although 149
patients (40%) who were not on warfarin treatment died and 18 patients (24 %) who
were on warfarin treatment died in sinus rhythm due to cardiovascular reasons during
follow-up (p¼0.006). We did not ﬁnd any statistical difference between patients with
warfarin user and patients who were not user in patients with pacemaker rhythm.
Conclusıon: It seemed patients who were taken warfarin had better outcomes in
patients with atrial ﬁbrillation and in patients with sinus rhythm in chronic HF.
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Depression Predicts Absence of Regular Physical Activity in Outpatients with
Systolic Heart Failure
Mehmet Birhan Yilmaz1, Hakan Altay2, Didem Oguz2, Nuryıl Yılmaz3,
Seckin Pehlivanoglu2
1Cumhuriyet University Faculty of Medicine, Department of Cardiology, Sivas,
2Bas¸kent University Hospital, Department of Cardiology, _Istanbul, 3Sivas State
Hospital, Psychiatry Clinic, Sivas
Heart failure (HF) is a common disease worldwide. On the other hand, regular
physical activity is beneﬁcial in terms of outcomes. In this study, parameters which
inﬂuence regular activity were investigated.
100 consecutive outpatients (age 6513 years, 54 males, 46 females) with stable
systolic heart failure (3110% ejection fraction) were enrolled. All patients were
asked for engagement with regular physical activity, and evaluated with Beck
depression inventory (BDI).
Results: 41 out of 100 patients stated that they engage regular physical activity with
a median of 3 days per week (ranging from 1-7 days/week). In the univariate analysis,
absence of regular physical activity was associated with female gender, lower ejection
fraction (EF), higher NYHA functional class, nonischemic etiology, presence of
therapy with spironolactone, higher BNP, BUN, longer duration of HF, lower plasma
sodium, higher tricuspid annular excursion (Table 1). Patients were classiﬁed into
two as those with presence of at least mild depression (BDI score 14) versus
those without depression. It was found that at least mild form of depression (BDI 14)
was found in 36.6% of patients having regular physical activity whereas, depression
was present in 88.1% of patients not having regular physical activity. Of note,
severe depression (BDI 29) was present in 7.3% and 49.2% respectively. Beck
depression score was able to predict absence of engagement in regular physical
activity in patients with HF (AUC¼0.827, p<0.001). In the stepwise regression
analysis, it was found that female gender (p¼0.010, ExpB¼4.251, 95%CI:1.417-
12.751), having at least mild depression by BDI (p¼0.0.10, ExpB¼4.639 95%
CI:1.451-14.829) and EF (p¼0.017, ExpB¼0.928, 95% CI:0.873-0.986) were found
to be independent predictors of absence of regular physical activity in stable outpa-
tients with systolic HF.
Conclusıon: Depression could potentially inﬂuence engagement in regular physical
activity in outpatients with systolic HF.l 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTERS
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The Relationship between Heart Failure Stage/Symptom Class and Depression
Etem Çelik1, Serkan Çay1, Sani Murat2, Fatih Öksüz1, Tayyar Cankurt1,
Mehmet Ali Mendi1
1Türkiye Yüksek _Ihtisas Hospital, Ankara, 2Ankara Training Hospital, Ankara
Background: Depression/depressive disorders are commonly encountered psychiatric
disorders. There is no data regarding the relationship between this commonly seen
situation and heart failure stage/class.
Aim: The aim of this study is to evaluate the relationship between various stages of
depression/depressive disorders and heart failure stages/classes.
Methods: A total of consecutive 419 patients with a mean age of 57.9  14.4 years
(age range, 18-96 years) admitted with the symptoms of heart failure and/or with risk
factors for heart failure were included in the study. Beck's depression inventory
including 21 evaluation sentences was applied to all study participants to measure the
level and severity of depression symptoms of persons. Measured total scores were
used to grade the severity as minimal (0-10), mild (11-16), moderate (17-29), and
severe (30-63).
Results: Two hundred and nineteen patients (52.3%) were male, 247 (58.9%) had
hypertension, 139 (33.2%) had diabetes, and 248 cases (59.2%) had coronary heart
disease. Stage A heart failure was present in 113 patients (27.0%), stage B in 119
patients (28.4%), stage C in 116 patients (27.7%), and stage D in remaining 71 cases
(16.9%). With regard to NYHA classiﬁcation, 228 patients (54.4%) had class I
symptoms, 101 (24.1%) had class II symptoms, 31 (7.4%) had class III symptoms, and
class IV symptoms were found in remaining 59 patients (14.1%). The mean left
ventricular ejection fraction of all population was 54.2%  12.4 and the mean Beck's
depression score was 12.4  11.1. It has been found that there was a signiﬁcant
positive relation between both heart failure stage and symptom class and depression
score. In addition, with increasing severity of heart failure stage and symptom class
the severity of depression increased (table). In univariate regression analysis, heart
failure stage, age, marital status, income level, education level, NYHA class, and beta
blocker use were risk factors for moderate-severe depression. In multivariate regres-
sion analysis, just heart failure stage (OR 4.99 and 95% CI 2.03-12.24, p<0.001) and
symptom class (OR 3.06 and 95% CI 1.39- 6.75, p¼0.005) were, however, deter-
mined as independent variables.
Conclusıon: Heart failure stage and symptom class were positively and independently
associated with the score and severity of depression.Heart failure
stage Stage A Stage B Stage C Stage D
P value
for trend
Depression
score
3.6  4.3 5.3  5.2 19.5  7.9 25.4  9.7 <0.001
NYHA class NYHA I NYHA II NYHA III NYHA IV
Depression
score
4.4  4.8 18.7  8.1 20.0  8.1 27.4  8.3 <0.001PP-054
Prognostic Role of Hematologic Parameters in Heart Failure Patients with
Incidental Massive Pleural Effusion Diagnosed During Echocardiographic
Evaluation
Süleyman Ercan1, Vedat Davutoglu1, Muhammed Oylumlu2, Mehmet Kaplan1,
_Ibrahim Halil _Inanç1
1Department of Cardiology, University of Gaziantep, Gaziantep, 2Department of
Cardiology, University of Dumlupınar, Kütahya
Aim: The prognostic signiﬁcance of patients with heart failure complicated with
pleural effusions determined by means of echocardiography is lacking. Thus we
sought to determine the prognostic signiﬁcance of hematologic parameters at heart
failure patients with pleural effusion which was evaluated incidentally during echo-
cardiographic evaluation.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTMethods: Between Jan 2002 and Dec 2012, total 151 patients with heart failure
suffered from pleural effusion analysed. All patients mortality data are derived from
registry center of Social Insurance Institution which ofﬁcially responsible for
recording all mortality data in Turkey. The diagnosis of patients’ pleural effusion
status were made during echocardiographic evaluation. We also evaluated hemato-
logical parameters including creatinine, uric acid, albumin, sodium, potassium,
hemoglobin at the time of hospital admission. Kaplan-Meir survival rates were
determined and subgroups were compared with log-rank test and Chi-square test.
Results: Total 151 eligible patients were analysed. Mean age was 6016.Male/
Female ratio was 97/54. Mean duration of follow-up was 71.5  45.6 months. Fifty-
one patients (33.8%) died during this follow-up period. There was not a signiﬁcant
difference regarding age and sex between survivors and those had died during follow-
up. There were no prognostic signiﬁcance of creatinine, uric acid, and potassium
levels. (p>0.05). However, albumin, sodium and hemoglobin levels were associated
with poor prognosis (p<0.0001, p¼0.001, and p¼0.009, respectively).
Conclusıon: Blood albumin, sodium, and hemoglobin levels have a worse prognostic
signiﬁcance in patient with heart failure complicated with pleural effusion determined
by means of echocardiography.PP-055
Even Slightly Elevated Plasma Uric Acid Levels Could be a Predictor of
Cardiovascular Death in Chronic Heart Failure
Yasar Akay1, Guliz Kozdag1, Ender Emre1, Tayfun Sahin1, Gokhan Ertas2,
Teoman Kilic1, Goksel Kahraman1, Ulas Bildirici1, Metin Cetin3, Umut Celikyurt1,
Kurtulus Karauzum1, Ertan Ural1, Dilek Ural1
1Kocaeli University, Faculty of Medicine, Department of Cardiology, Kocaeli,
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Cerkezkoy, Tekirdag
Background: Recent ﬁndings suggest that there is a close relationship between
chronic heart failure and uric acid (UA). UA is the ﬁnal product of purine metabolism
in humans and is implicated in many disease conditions. Sustained hyperuricaemia has
putative adverse roles in cardiovascular diseases. It was determined that elevated UA
levels could be a risk factor for cardiac dysfunction. Increased serum uric acid levels
may be an important prognostic marker in chronic heart failure (CHF).
Methods: A total of 593 CHF patients with measured UA levels, creatinine levels,
urea levels, BNP levels and hs-CRP levels, ejection fraction between May 2003 and
January 2009 were evaluated, (382 males, 211 females mean age 6313 years, mean
ejection fraction 2610 %, mean New York Heart Association (NYHA) class
2.80.5). Mean UA level was 7.52.6 mg/dL. While 64% of patients had coronary
artery disease (CAD), 26 % patients had chronic renal disease (CRD). The cardio-
vascular death was accepted as an endpoint.
Results: 36% of patients were died due to cardiovascular reason in this group. Patients
who met end point criteria was older and had higher NYHA class, urea levels, BNP
levels, hs-CRP levels, UA levels, lower ejection fraction, increased right ventricular
(RV) dimension and higher pulmonary artery pressure. In multivariate analysis, when
UA levels were adjusted for a second parameters (age, gender, NYHA, CAD, CRD,
urea, hs-CRP, RV), the risk of death remained signiﬁcant after each adjustment.
Moreover, age (hazard ratio (HR): 1.055, 95%CI: 1.035-1.075, p<0.001), NYHA
class (HR: 3.675, 95%CI: 2.222-6.079, p<0.001) and UA (HR: 1.154, 95%CI: 1.067-
1.248, p<0.001) and hs-RCP (HR: 1.091, 95%CI: 1.032-1.153, p<0.001) appear to
be important factors to determine the cardiovascular death in CHF patients. The
predictive cutoff value of UA levels for cardiovascular death was evaluated in
Receiver operating characteristic (ROC) curve analysis. The area under the curve for
UA was 0.629 (95% CI, 0.582–0.675; P<0.001). ROC curve analysis showed that
4.65 mg/dL UA level had 93% sensitivity and 86% speciﬁcity for cardiovascular
death.
Conclusıon: Increased UA levels were an independent predictor in CHF. Even
slightly increased UA levels could be a predictor for cardiovascular death in patients
with CHF.ERS C103
